Allakos (ALLK)
(Delayed Data from NSDQ)
$0.66 USD
-0.04 (-5.40%)
Updated Aug 9, 2024 04:00 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALLK 0.66 -0.04(-5.40%)
Will ALLK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALLK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLK
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
ALLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
Other News for ALLK
Maintaining Hold on Allakos: Weighing AK006 Promise Against Clinical Setbacks
Allakos GAAP EPS of -$0.30
Allakos’s Promising Drug and Financial Health Garner a Buy Rating
Piper Sandler Remains a Buy on Allakos (ALLK)
Barclays Sticks to Its Sell Rating for Allakos (ALLK)